Cancer Predisposition Syndrome

3

Review clinical trials related to Cancer Predisposition Syndrome. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Prenatal Transplantation for Fetuses With Fanconi Anemia

The investigators aim to evaluate the safety and efficacy of in utero hematopoietic stem cell transplantation (IUHSCT) for the treatment of fetuses diagnosed with Fanconi anemia (FA) during pregnancy.

Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Biological sex: AllType: InterventionalSponsor: Agnieszka CzechowiczUpdated: Jun 16, 2026Locations: 2
Eligibility criteria

Male or female fetuses from 19^0/7 - 28^0/7 weeks gestational age at time of tra... [+3]

Fetal Participant Exclusion Criteria: Major anatomic or genetic anomalies that c... [+1]

Status: Recruiting

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study

The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test

Participants needed: 1,000
Trial details
Age: 22+Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Jan 20, 2026Locations: 1
Eligibility criteria

Age ≥ 22 for patients with TP53 germline pathogenic variants, age ≥ 35 for all o... [+11]

Individuals diagnosed with invasive malignancy within 3 years of enrollment [+6]

Status: Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Participants needed: 5,000
Trial details
Biological sex: AllType: ObservationalSponsor: Dana-Farber Cancer InstituteUpdated: Aug 7, 2025Locations: 1Duration: 20 Years
Eligibility criteria

Carriers of known or previously unrecognized pathogenic germline variants of can... [+22]